Abstract:ABSTRACT Candida albicans causes life-threatening invasive infections that are hard to diagnose and treat, with drug resistance leading to treatment failure. The goal of this study was to develop VHH (single variable domain on a heavy chain) nanobodies to detect drug-resistant infections. Llamas were immunized with a mixture of heat killed and fixed C. albicans cells of different morphologies. Llama lymphocyte RNA was used to generate phage display libraries that were tested for binding to C. albicans cells or cell wall fractions, and single antibody domains were isolated. The libraries were panned against echinocandin-resistant C. albicans isolates and counter-selected against echinocandin-susceptible isolates with the aim of isolating binding domains specific for antigens on drug-resistant cells. Thirty diverse VHH nanobodies were selected, and binding characteristics were assessed via dose-response ELISA. Binding was tested against a variety of C. albicans isolates and other Candida species, indicating that the VHHs were specific for C. albicans . The VHH nanobodies were sorted into four distinct groups based on their binding patterns. Two of the groups bound preferentially to the yeast cell poles and hyphae, respectively. Nanobody binding to C. albicans deletion mutants was tested by fluorescence microscopy and ELISA to identify the antigen targets. VHH19 nanobody, belonging to the largest group, recognized the Als4 adhesin. VHH14 antibody in the hyphae-specific group recognized Als3. None of the isolated VHH nanobodies was selective for drug-resistant clinical isolates. Our data indicate that this approach can generate valuable single-domain antibodies specific to C. albicans proteins. IMPORTANCE The human fungal pathogen Candida albicans causes a range of diseases from superficial mucosal infections such as oral and vaginal thrush to life-threatening, systemic infections. Accurate and rapid diagnosis of these infections remains challenging, and currently, there are no rapid ways to diagnose drug-resistant infections without performing drug susceptibility testing from blood culture, which can take several days. In this proof-of-concept study, we have generated a diverse set of single domain VHH antibodies (nanobodies) from llamas that recognize and bind specifically to C. albicans cell surface. The nanobodies were classified into four groups based on their binding patterns, for example, cell poles or hyphae. Specific nanobodies were verified as recognizing the important adhesin Als4 or the hyphae associated invasin Als3, respectively. The data validate the approach that small VHH antibody domains hold future promise for diagnostic applications and as probes to study the fungal cell surface.

Candida albicans cDNA Library Screening Reveals Novel Potential Diagnostic Targets for Invasive Candidiasis

Anti-Candida Antibodies of Patients with Invasive Candidiasis Inhibit Growth, Alter Cell Wall Structure, and Kill Candida albicans In Vitro

Screening clinical Candida albicans isolates for invasiveness by mimicking the human environment

Robust Fluorometric Aptamer Assay for Direct and Rapid Detection of Clinical Isolates of Candida spec.

Quantitatively detecting Candida albicans enolase1 with a one-step double monoclonal antibody sandwich ELISA assay

The development of single-domain VHH nanobodies that target the Candida albicans cell surface

Identification of various medically important Candida species in clinical specimens by PCR-restriction enzyme analysis

Improved detection of Candida albicans by PCR in blood of neutropenic mice with systemic candidiasis

Simple and Rapid Detection of Candida albicans DNA in Serum by PCR for Diagnosis of Invasive Candidiasis

A genome-scale screen identifies sulfated glycosaminoglycans as pivotal in epithelial cell damage by Candida albicans

Detection of some virulence factors among Candida albicans isolated from patients and prevalence of candidalysin gene CEEc1

A Real Time PCR strategy for the detection and quantification of Candida albicans in human blood

The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis

Lower (1,3)-beta-d-glucan (BDG) sensitivity and in-vitro levels in Candida auris and Candida parapsilosis strains

Detection and Molecular Identification of Eight Candida Species in Clinical Samples by Simplex PCR

[Is the use of antifungal management advisable in critical patients with positive isolation of Candida spp. from intraabdominal clinical samples?]

Sulfated glycosaminoglycans are host epithelial cell targets of the Candida albicans toxin candidalysin

Breaking barriers: the fungal toxin candidalysin disrupts epithelial integrity and induces inflammation in a gut-on-chip model

A novel, rapid, ultrasensitive diagnosis platform for detecting Candida albicans using restriction endonuclease‐mediated real-time loop-mediated isothermal amplification

Molecular Genotyping of Candida Albicans Isolated from Different Sites May Trace the Etiological Infection Routes: Observation in China

Identification of differentially expressed genes and signaling pathways with Candida infection by bioinformatics analysis